HESI Exit V2 Exam Bank | 250 Questions & Answers
(Verified Answers) With Rationales, 100% Guaranteed Pass ||
Complete A+ Guide
HESI Exit V2 Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100%
Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam bank contains 250 verified questions and answers with detailed rationales,
designed to prepare nursing students for the HESI Exit V2 exam. Each question is aligned with the
latest NCLEX and HESI standards, ensuring coverage of essential nursing concepts. The rationales
provide in-depth explanations of correct and incorrect options, promoting critical thinking and
retention. This resource is guaranteed to help students achieve a passing score and excel on their exit
examination.
Key Features:
250 verified questions with rationales
Comprehensive coverage of medical-surgical, maternal-newborn, pediatric, psychiatric, and community health
nursing
Updated for 2026/2027 academic year with latest clinical guidelines
Detailed rationales for each answer, including distractor analysis
Organized by content area for focused study
100% pass guarantee with proven success
Updates for 2026:
- Revised to reflect 2026-2027 NCLEX and HESI test plan updates
- Added new questions on emerging healthcare topics (e.g., telehealth, COVID-19 management)
- Enhanced rationales with evidence-based practice references
- Improved answer format for clarity and consistency
- Incorporated student feedback for better learning outcomes
Abstract:
The HESI Exit V2 Exam Bank is a meticulously curated collection of 250 multiple-choice questions designed to
assess and reinforce the knowledge required for the HESI exit examination. Each question is accompanied by a
verified answer and a comprehensive rationale that explains the underlying concepts and clinical reasoning. The
exam bank covers all major nursing content areas, including medical-surgical, maternal-newborn, pediatric,
psychiatric, and community health nursing, with a focus on high-yield topics. The rationales are structured to help
students understand why each answer is correct or incorrect, thereby enhancing their critical thinking and
decision-making skills. This resource is updated annually to align with the latest evidence-based practice and exam
guidelines, ensuring that students are studying the most current material. With a 100% pass guarantee, this exam
bank is an essential tool for nursing students preparing for their exit exam and subsequent licensure.
Keywords:
HESI Exit V2, Nursing exam bank, 250 questions, Verified answers, Rationales, NCLEX preparation, Nursing exit
exam, 2026-2027
Answer Format:
Each question is presented in a multiple-choice format with four options. The correct answer is clearly indicated,
followed by a rationale that explains the reasoning behind the correct choice and why the other options are
incorrect. Rationales include clinical references and evidence-based practice insights to reinforce learning.
Page 1
,Compliance Checklist:
Aligned with 2026-2027 HESI and NCLEX test plans
All answers verified by nursing experts
Rationales include evidence-based practice references
Questions cover all major nursing content areas
Updated per latest clinical guidelines
Guaranteed to help achieve a passing score
Content Area Overview:
Content Area Questions Key Topics Weight
Medical-Surgical Nursing 1-70 Cardiovascular, Respiratory, 28%
Gastrointestinal, Endocrine, Neurological
Maternal-Newborn Nursing 71-110 Antepartum, Intrapartum, Postpartum, 16%
Newborn Care, Complications
Pediatric Nursing 111-150 Growth and Development, Common 16%
Illnesses, Immunizations, Pediatric
Emergencies
Psychiatric Nursing 151-190 Therapeutic Communication, Mental Health 16%
Disorders, Psychopharmacology, Crisis
Intervention
Community Health Nursing 191-220 Epidemiology, Health Promotion, Disaster 12%
Management, Vulnerable Populations
Leadership and Management 221-250 Delegation, Prioritization, Ethics, Legal 12%
Issues, Quality Improvement
Page 2
,Q1. A client with chronic kidney disease (CKD) stage 4 is being evaluated for anemia. Laboratory results
show hemoglobin 8.5 g/dL, MCV 78 fL, ferritin 45 ng/mL, transferrin saturation 15%, and eGFR 25
mL/min/1.73 m². The provider orders erythropoiesis-stimulating agent (ESA) therapy. Which additional
assessment is most critical to address before initiating ESA therapy?
A. Blood pressure measurement and antihypertensive medication adjustment
B. Serum potassium level and ECG monitoring for hyperkalemia
C. Iron studies and initiation of iron supplementation
D. Parathyroid hormone level and phosphate binder prescription
Correct Answer: C. Iron studies and initiation of iron supplementation
Rationale: ESA therapy is ineffective in the presence of iron deficiency. The client has absolute iron deficiency
(ferritin <100 ng/mL, TSAT <20%), so iron supplementation must precede or accompany ESA to optimize
erythropoiesis. Hypertension is a common side effect of ESAs but is not the most critical prerequisite; iron status is
essential for response. Hyperkalemia and hyperparathyroidism are relevant in CKD but do not directly impair ESA
efficacy.
Why Wrong:
A - Blood pressure management is important during ESA therapy but not the most critical prerequisite for
initiating therapy.
B - Hyperkalemia is a concern in CKD but does not directly affect the response to ESA therapy.
D - Secondary hyperparathyroidism is a complication of CKD but does not impair ESA efficacy.
Reference: National Kidney Foundation. (2020). KDOQI Clinical Practice Guideline for Anemia in Chronic
Kidney Disease. Am J Kidney Dis, 75(2 Suppl 1), S1-S164.
Q2. A research team is analyzing the binding affinity of a novel drug candidate to a G-protein-coupled
receptor (GPCR). They observe that the drug requires a higher concentration to achieve half-maximal
binding compared to the endogenous ligand, but once bound, it produces a submaximal response even at
saturation. Which pharmacological property best describes this drug?
A. Partial agonist with low potency
B. Full agonist with low efficacy
C. Competitive antagonist with high affinity
D. Inverse agonist with low intrinsic activity
Correct Answer: A. Partial agonist with low potency
Rationale: The drug has lower potency (higher EC50) than the endogenous ligand, indicating lower affinity or
efficacy, and produces a submaximal response at saturation, defining it as a partial agonist. Low potency is
reflected in the higher concentration needed for half-maximal binding. Full agonists produce maximal response;
competitive antagonists produce no response; inverse agonists decrease constitutive activity.
Why Wrong:
B - A full agonist would produce maximal response at saturation, not submaximal.
C - A competitive antagonist would produce no response, only shift the dose-response curve rightward.
D - An inverse agonist reduces basal activity, which is not described here.
Reference: Brunton, L.L., et al. (2018). Goodman & Gilman's The Pharmacological Basis of Therapeutics, 13th
Ed., Ch. 3.
Q3. A client with a history of recurrent urinary tract infections (UTIs) is prescribed nitrofurantoin for
prophylaxis. The nurse reviews the prescription and notes that the client has an eGFR of 35 mL/min/1.73 m².
What is the most appropriate nursing action?
A. Administer the medication as prescribed because nitrofurantoin is safe at any eGFR.
B. Hold the medication and consult the provider due to risk of pulmonary toxicity at low eGFR.
C. Administer a reduced dose adjusted for renal function.
D. Administer the medication with increased fluid intake to prevent crystalluria.
Page 3
, Correct Answer: B. Hold the medication and consult the provider due to risk of pulmonary toxicity at low
eGFR.
Rationale: Nitrofurantoin is contraindicated when eGFR is <30-45 mL/min because it accumulates and increases risk of
peripheral neuropathy and pulmonary toxicity. The nurse should hold the medication and notify the provider. Dose adjustment
is not recommended because efficacy is reduced and toxicity risk increases. Crystalluria is not a primary concern with
nitrofurantoin.
Why Wrong:
A - Nitrofurantoin is not safe at low eGFR; it accumulates and causes toxicity.
C - Dose adjustment is not recommended; the drug should be avoided entirely at eGFR <30-45.
D - Increased fluid intake does not prevent the accumulation and toxicity of nitrofurantoin.
Reference: Micromedex. (2025). Nitrofurantoin: Renal Impairment. Truven Health Analytics.
Q4. A client in the intensive care unit develops hypotension, tachycardia, and a drop in oxygen saturation
after receiving intravenous vancomycin. The nurse notes flushing, urticaria on the chest, and angioedema of
the lips. Which intervention should the nurse perform first?
A. Administer diphenhydramine 50 mg IV push.
B. Stop the vancomycin infusion and maintain IV access.
C. Administer epinephrine 0.3 mg intramuscularly.
D. Obtain a serum tryptase level and blood cultures.
Correct Answer: B. Stop the vancomycin infusion and maintain IV access.
Rationale: This presentation is consistent with anaphylaxis. The immediate priority is to discontinue the offending
agent (vancomycin) and maintain IV access for emergency medications. Epinephrine is the first-line treatment for
anaphylaxis, but the nurse must first stop the infusion. Diphenhydramine is a secondary treatment. Tryptase levels
are diagnostic, not immediate treatment.
Why Wrong:
A - Diphenhydramine is a secondary treatment and not the first priority in anaphylaxis.
C - Epinephrine should be given, but stopping the infusion is the immediate first action.
D - Diagnostic tests are not the first intervention; treatment takes priority.
Reference: Lieberman, P., et al. (2015). Anaphylaxis-a practice parameter update. Ann Allergy Asthma Immunol,
115(5), 341-384.
Q5. A client with a history of type 2 diabetes mellitus and hypertension is prescribed lisinopril. Which
laboratory value is most important for the nurse to monitor before and during therapy?
A. Serum creatinine and potassium levels
B. Blood glucose and hemoglobin A1c
C. Serum sodium and chloride levels
D. Liver function tests including ALT and AST
Correct Answer: A. Serum creatinine and potassium levels
Rationale: ACE inhibitors like lisinopril can cause hyperkalemia and acute kidney injury, especially in clients with
baseline renal impairment or those taking other nephrotoxic drugs. Monitoring serum creatinine and potassium is
essential. Blood glucose is not directly affected by ACE inhibitors. Sodium and chloride are not typically
monitored. Liver function is not a primary concern with ACE inhibitors.
Why Wrong:
B - Lisinopril does not directly affect blood glucose or hemoglobin A1c.
C - Sodium and chloride levels are not significantly altered by ACE inhibitors.
D - ACE inhibitors are not known to cause hepatotoxicity; liver function monitoring is not required.
Reference: Messerli, F.H., & Bangalore, S. (2021). ACE Inhibitors. In: Antihypertensive Therapy. Springer.
Page 4
(Verified Answers) With Rationales, 100% Guaranteed Pass ||
Complete A+ Guide
HESI Exit V2 Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100%
Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam bank contains 250 verified questions and answers with detailed rationales,
designed to prepare nursing students for the HESI Exit V2 exam. Each question is aligned with the
latest NCLEX and HESI standards, ensuring coverage of essential nursing concepts. The rationales
provide in-depth explanations of correct and incorrect options, promoting critical thinking and
retention. This resource is guaranteed to help students achieve a passing score and excel on their exit
examination.
Key Features:
250 verified questions with rationales
Comprehensive coverage of medical-surgical, maternal-newborn, pediatric, psychiatric, and community health
nursing
Updated for 2026/2027 academic year with latest clinical guidelines
Detailed rationales for each answer, including distractor analysis
Organized by content area for focused study
100% pass guarantee with proven success
Updates for 2026:
- Revised to reflect 2026-2027 NCLEX and HESI test plan updates
- Added new questions on emerging healthcare topics (e.g., telehealth, COVID-19 management)
- Enhanced rationales with evidence-based practice references
- Improved answer format for clarity and consistency
- Incorporated student feedback for better learning outcomes
Abstract:
The HESI Exit V2 Exam Bank is a meticulously curated collection of 250 multiple-choice questions designed to
assess and reinforce the knowledge required for the HESI exit examination. Each question is accompanied by a
verified answer and a comprehensive rationale that explains the underlying concepts and clinical reasoning. The
exam bank covers all major nursing content areas, including medical-surgical, maternal-newborn, pediatric,
psychiatric, and community health nursing, with a focus on high-yield topics. The rationales are structured to help
students understand why each answer is correct or incorrect, thereby enhancing their critical thinking and
decision-making skills. This resource is updated annually to align with the latest evidence-based practice and exam
guidelines, ensuring that students are studying the most current material. With a 100% pass guarantee, this exam
bank is an essential tool for nursing students preparing for their exit exam and subsequent licensure.
Keywords:
HESI Exit V2, Nursing exam bank, 250 questions, Verified answers, Rationales, NCLEX preparation, Nursing exit
exam, 2026-2027
Answer Format:
Each question is presented in a multiple-choice format with four options. The correct answer is clearly indicated,
followed by a rationale that explains the reasoning behind the correct choice and why the other options are
incorrect. Rationales include clinical references and evidence-based practice insights to reinforce learning.
Page 1
,Compliance Checklist:
Aligned with 2026-2027 HESI and NCLEX test plans
All answers verified by nursing experts
Rationales include evidence-based practice references
Questions cover all major nursing content areas
Updated per latest clinical guidelines
Guaranteed to help achieve a passing score
Content Area Overview:
Content Area Questions Key Topics Weight
Medical-Surgical Nursing 1-70 Cardiovascular, Respiratory, 28%
Gastrointestinal, Endocrine, Neurological
Maternal-Newborn Nursing 71-110 Antepartum, Intrapartum, Postpartum, 16%
Newborn Care, Complications
Pediatric Nursing 111-150 Growth and Development, Common 16%
Illnesses, Immunizations, Pediatric
Emergencies
Psychiatric Nursing 151-190 Therapeutic Communication, Mental Health 16%
Disorders, Psychopharmacology, Crisis
Intervention
Community Health Nursing 191-220 Epidemiology, Health Promotion, Disaster 12%
Management, Vulnerable Populations
Leadership and Management 221-250 Delegation, Prioritization, Ethics, Legal 12%
Issues, Quality Improvement
Page 2
,Q1. A client with chronic kidney disease (CKD) stage 4 is being evaluated for anemia. Laboratory results
show hemoglobin 8.5 g/dL, MCV 78 fL, ferritin 45 ng/mL, transferrin saturation 15%, and eGFR 25
mL/min/1.73 m². The provider orders erythropoiesis-stimulating agent (ESA) therapy. Which additional
assessment is most critical to address before initiating ESA therapy?
A. Blood pressure measurement and antihypertensive medication adjustment
B. Serum potassium level and ECG monitoring for hyperkalemia
C. Iron studies and initiation of iron supplementation
D. Parathyroid hormone level and phosphate binder prescription
Correct Answer: C. Iron studies and initiation of iron supplementation
Rationale: ESA therapy is ineffective in the presence of iron deficiency. The client has absolute iron deficiency
(ferritin <100 ng/mL, TSAT <20%), so iron supplementation must precede or accompany ESA to optimize
erythropoiesis. Hypertension is a common side effect of ESAs but is not the most critical prerequisite; iron status is
essential for response. Hyperkalemia and hyperparathyroidism are relevant in CKD but do not directly impair ESA
efficacy.
Why Wrong:
A - Blood pressure management is important during ESA therapy but not the most critical prerequisite for
initiating therapy.
B - Hyperkalemia is a concern in CKD but does not directly affect the response to ESA therapy.
D - Secondary hyperparathyroidism is a complication of CKD but does not impair ESA efficacy.
Reference: National Kidney Foundation. (2020). KDOQI Clinical Practice Guideline for Anemia in Chronic
Kidney Disease. Am J Kidney Dis, 75(2 Suppl 1), S1-S164.
Q2. A research team is analyzing the binding affinity of a novel drug candidate to a G-protein-coupled
receptor (GPCR). They observe that the drug requires a higher concentration to achieve half-maximal
binding compared to the endogenous ligand, but once bound, it produces a submaximal response even at
saturation. Which pharmacological property best describes this drug?
A. Partial agonist with low potency
B. Full agonist with low efficacy
C. Competitive antagonist with high affinity
D. Inverse agonist with low intrinsic activity
Correct Answer: A. Partial agonist with low potency
Rationale: The drug has lower potency (higher EC50) than the endogenous ligand, indicating lower affinity or
efficacy, and produces a submaximal response at saturation, defining it as a partial agonist. Low potency is
reflected in the higher concentration needed for half-maximal binding. Full agonists produce maximal response;
competitive antagonists produce no response; inverse agonists decrease constitutive activity.
Why Wrong:
B - A full agonist would produce maximal response at saturation, not submaximal.
C - A competitive antagonist would produce no response, only shift the dose-response curve rightward.
D - An inverse agonist reduces basal activity, which is not described here.
Reference: Brunton, L.L., et al. (2018). Goodman & Gilman's The Pharmacological Basis of Therapeutics, 13th
Ed., Ch. 3.
Q3. A client with a history of recurrent urinary tract infections (UTIs) is prescribed nitrofurantoin for
prophylaxis. The nurse reviews the prescription and notes that the client has an eGFR of 35 mL/min/1.73 m².
What is the most appropriate nursing action?
A. Administer the medication as prescribed because nitrofurantoin is safe at any eGFR.
B. Hold the medication and consult the provider due to risk of pulmonary toxicity at low eGFR.
C. Administer a reduced dose adjusted for renal function.
D. Administer the medication with increased fluid intake to prevent crystalluria.
Page 3
, Correct Answer: B. Hold the medication and consult the provider due to risk of pulmonary toxicity at low
eGFR.
Rationale: Nitrofurantoin is contraindicated when eGFR is <30-45 mL/min because it accumulates and increases risk of
peripheral neuropathy and pulmonary toxicity. The nurse should hold the medication and notify the provider. Dose adjustment
is not recommended because efficacy is reduced and toxicity risk increases. Crystalluria is not a primary concern with
nitrofurantoin.
Why Wrong:
A - Nitrofurantoin is not safe at low eGFR; it accumulates and causes toxicity.
C - Dose adjustment is not recommended; the drug should be avoided entirely at eGFR <30-45.
D - Increased fluid intake does not prevent the accumulation and toxicity of nitrofurantoin.
Reference: Micromedex. (2025). Nitrofurantoin: Renal Impairment. Truven Health Analytics.
Q4. A client in the intensive care unit develops hypotension, tachycardia, and a drop in oxygen saturation
after receiving intravenous vancomycin. The nurse notes flushing, urticaria on the chest, and angioedema of
the lips. Which intervention should the nurse perform first?
A. Administer diphenhydramine 50 mg IV push.
B. Stop the vancomycin infusion and maintain IV access.
C. Administer epinephrine 0.3 mg intramuscularly.
D. Obtain a serum tryptase level and blood cultures.
Correct Answer: B. Stop the vancomycin infusion and maintain IV access.
Rationale: This presentation is consistent with anaphylaxis. The immediate priority is to discontinue the offending
agent (vancomycin) and maintain IV access for emergency medications. Epinephrine is the first-line treatment for
anaphylaxis, but the nurse must first stop the infusion. Diphenhydramine is a secondary treatment. Tryptase levels
are diagnostic, not immediate treatment.
Why Wrong:
A - Diphenhydramine is a secondary treatment and not the first priority in anaphylaxis.
C - Epinephrine should be given, but stopping the infusion is the immediate first action.
D - Diagnostic tests are not the first intervention; treatment takes priority.
Reference: Lieberman, P., et al. (2015). Anaphylaxis-a practice parameter update. Ann Allergy Asthma Immunol,
115(5), 341-384.
Q5. A client with a history of type 2 diabetes mellitus and hypertension is prescribed lisinopril. Which
laboratory value is most important for the nurse to monitor before and during therapy?
A. Serum creatinine and potassium levels
B. Blood glucose and hemoglobin A1c
C. Serum sodium and chloride levels
D. Liver function tests including ALT and AST
Correct Answer: A. Serum creatinine and potassium levels
Rationale: ACE inhibitors like lisinopril can cause hyperkalemia and acute kidney injury, especially in clients with
baseline renal impairment or those taking other nephrotoxic drugs. Monitoring serum creatinine and potassium is
essential. Blood glucose is not directly affected by ACE inhibitors. Sodium and chloride are not typically
monitored. Liver function is not a primary concern with ACE inhibitors.
Why Wrong:
B - Lisinopril does not directly affect blood glucose or hemoglobin A1c.
C - Sodium and chloride levels are not significantly altered by ACE inhibitors.
D - ACE inhibitors are not known to cause hepatotoxicity; liver function monitoring is not required.
Reference: Messerli, F.H., & Bangalore, S. (2021). ACE Inhibitors. In: Antihypertensive Therapy. Springer.
Page 4
